article thumbnail

Is it too late for Biogen?

World of DTC Marketing

Never mind that physicians have turned against the drug Biogen wants to fight the decision because of their business needs. Food and Drug Administration on Biogen Inc.’s ” A physician on STAT News wrote, “the consequences of FDA approval are as disturbing as they are vast. Top researchers who advised the U.S.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Unpaid celebrity endorsements include venture capitalist Marc Andreessen, who says the drug completely changed his relationship with food, and Elon Musk, who has cited it on Twitter. It has to persuade patients to sign up for some heinous side effects. So far, the data for Wegovy looks excellent.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

article thumbnail

Getting an Rx does not address health problems

World of DTC Marketing

Lilly’s new diabetes drug is being talked about all over social media because of its weight loss properties, but what’s not mentioned is that it requires a diet modification and has side effects that can cause more severe health issues. Why don’t doctors have the “the talk”?

Insurance 200
article thumbnail

Cerner Enviza and FDA partner to develop AI drug safety tools

Pharmaceutical Technology

Oracle company Cerner Enviza and John Snow Labs have collaborated with the US Food and Drug Administration (FDA) for the development of artificial intelligence (AI) tools for drug safety and real-world evidence studies. During the two-year project, the companies will assess the mental health side effects of the asthma drug, montelukast.

Safety 59
article thumbnail

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses.

article thumbnail

FDA accepts Ardelyx’s NDA resubmission for XPHOZAH

Pharma Leaders

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.